# Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification

> **NCT03693989** · PHASE3 · COMPLETED · sponsor: **Laboratorios Sophia S.A de C.V.** · enrollment: 178 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** Difluprednate 0.05%
- **DRUG:** Prednefrin

## Key facts

- **NCT ID:** NCT03693989
- **Lead sponsor:** Laboratorios Sophia S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-04
- **Primary completion:** 2019-08-07
- **Final completion:** 2019-10-22
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2019-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693989, "Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03693989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*